Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The cooperation among the core regulatory circuitry transcription factors and MYCN on DNA binding [HAND2-MYCN-CRC-knockdown_ChIPseq]

ABSTRACT: The cooperation among the core regulatory circuitry transcription factors and MYCN on DNA binding [HAND2-MYCN-CRC-knockdown_ChIPseq]

PROVIDER: PRJNA762917 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15881401.fastq.gz	Fastqsanger.gz
	SRR15881402.fastq.gz	Fastqsanger.gz
	SRR15881403.fastq.gz	Fastqsanger.gz
	SRR15881404.fastq.gz	Fastqsanger.gz
	SRR15881405.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 36

Similar Datasets

The cooperation among the core regulatory circuitry transcription factors and MYCN on DNA binding [HAND2-MYCN-CRC-knockdown_ChIPseq]

Project description:MYCN and the core regulatory circuitry transcription factors HAND2, PHOX2B and GATA3 cooperate to bind to DNA.

2023-03-29 | GSE184057 | GEO

The cooperation between HAND2 and MYCN on DNA binding [HAND2-overexpression_ChIPseq]

Project description:The cooperation between HAND2 and MYCN on DNA binding [HAND2-overexpression_ChIPseq]

| PRJNA762920 | ENA

The cooperation between HAND2 and MYCN on DNA binding [HAND2-overexpression_ChIPseq]

Project description:HAND2 assists MYCN bind to DNA.

2023-03-29 | GSE184059 | GEO

KDM4 inhibition disrupts the core regulatory transcriptional circuitry in MYCN-driven neuroblastoma [Cut&Tag]

Project description:A small set of interconnected lineage-specific transcription factors (TFs) form a core regulatory circuitry (CRC) that establishes and maintains cell identity and grants selective dependencies of distinct cancer types. However, effective therapies to targeting CRC TFs remain lacking. Here, we show that the best-in-class KDM4 inhibitor QC6352 has a potent anticancer activity in MYCN-driven high-risk neuroblastoma and significantly represses the CRC TFs including MYCN, HAND2, ASCL1, PHOX2B by disrupting the super-enhancers that dominate the expression of CRC TFs. Furthermore, we have developed a combination therapy by integrating QC6352 into cytotoxic chemotherapy, which leads to a complete response of MYCN amplified tumors and a better animal survival. This study reveals that targeting histone lysine demethylase 4 family may transform into a therapeutic strategy in clinic for cancers driven by CRC TFs.

2024-03-04 | GSE164454 | GEO

KDM4 inhibition disrupts the core regulatory transcriptional circuitry in MYCN-driven neuroblastoma [ChIP-seq]

2024-03-04 | GSE164451 | GEO